leadf
logo-loader
viewLineage Cell Therapeutics

Lineage Cell Therapeutics: Meet the ‘hidden gem’ cell therapy specialist with three clinical stage assets

With three clinical-stage assets, the $140 million market capitalization looks anomalous and suggests that Lineage is flying well below the radar

Lineage Cell Therapeutics -

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is a clinical-stage biotechnology company developing cell therapies for unmet medical needs.

It is working in the areas of eye disease, spinal cord injuries and cancer immuno-therapy.

With three clinical-stage assets, the $140 million market capitalization looks anomalous and suggests that Lineage is flying well below the radar.

Join us at 1pm EST on October 14 at our One2One virtual investor conference to learn more about this hidden gem of the world of life sciences.

CLICK HERE TO REGISTER

About the event:

  • Ours is an audience of astute high net worth investors, fund managers, private client brokers and analysts
  • We look beyond the numbers and meet the people creating the value for shareholders

The format:

  • Each company has a presentation slot followed by Q & A, giving you the chance to discover the real story
  • You can watch the event afterwards on our YouTube channel

CLICK HERE TO REGISTER

Quick facts: Lineage Cell Therapeutics

Price: 1.29 USD

NYSE:LCTX
Market: NYSE
Market Cap: $193.48 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lineage Cell Therapeutics named herein, including the promotion by the Company of Lineage Cell Therapeutics in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Lineage Cell Therapeutics busy working on treatments relating to Dry AMD and...

Lineage Cell Therapeutics (NYSE AMERICAN: LCTX) CEO Brian Culley and CFO Brandi Roberts joined Steve Darling from Proactive to share details about their proprietary cell-based therapy platform. The Company is using that platform to advance a pipeline of novel candidates for the treatment of...

2 weeks, 5 days ago

2 min read